RELMADA THERAPEUTICS, INC. — fact timeline

RELMADA THERAPEUTICS, INC. shareholders approved Approval of the Charter Amendment to increase authorized shares at the 2026-05-27 meeting.

“Proposal 4: Approval of the Charter Amendment Stockholders approved the proposed amendment to the Company’s Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from 150,000,000 to 200,000,000. The Charter Amendment is described in more detail in the Company’s 2026 Proxy Statement, which was filed with the Securities and Exchange Commission on April 17, 2026 For Against Withheld Broker Non-Votes 65,072,921 1,170,378 328,412 -”

RELMADA THERAPEUTICS, INC. shareholders approved Approval of an Amendment to the 2021 Plan at the 2026-05-27 meeting.

“Proposal 3: Approval of an Amendment to the 2021 Plan. Stockholders approved the proposed amendment to the Company’s 2021 Equity Incentive Plan, as amended (the “2021 Plan”), to increase the number of shares of the Company’s common stock available for issuance pursuant to awards under the 2021 Plan by 3,000,000 to an aggregate of 18,052,942 (including awards previously granted). The 2021 Plan is described in more detail in the Company’s 2026 Proxy Statement, which was filed with the Securities and Exchange Commission on April 17, 2026. For Against Withheld Broker Non-Votes 36,480,855 18,181,681 85,048 11,824,127”

RELMADA THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Independent Auditors at the 2026-05-27 meeting.

“Proposal 2: Ratification of Appointment of Independent Auditors. Stockholders approved the ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Withheld Broker Non-Votes 66,097,327 104,854 369,530 -”

RELMADA THERAPEUTICS, INC. shareholders approved Election of Directors at the 2026-05-27 meeting.

“Proposal 1: Election of Directors. Stockholders elected the following nominees as directors to hold office until the 2029 Annual Meeting (i.e. as a Class II Director) and until his successor is elected and qualified or until his earlier resignation or removal. Nominee For Withheld Broker Non-Votes Charles J. Casamento (Class II, 36 month term) 33,859,106 20,888,478 11,824,127 Sergio Traversa (Class II, 36 month term) 54,124,764 622,820 11,824,127”

RELMADA THERAPEUTICS, INC.: Increased authorized common shares from 150,000,000 to 200,000,000 (effective 2026-05-28).

“On May 28, 2026, Relmada Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation, as amended, with the Secretary of State of Nevada to increase the number of authorized shares of the Company’s common stock from 150,000,000 to 200,000,000 shares (the “ Charter Amendment ”).”

RELMADA THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2025.

“Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update”

RELMADA THERAPEUTICS, INC. issued up to 4,210,527 shares of Common Stock of warrant to certain institutional and accredited investors for $4.749 per Pre-Funded Warrant.

“of approximately $160.0 million, an aggregate of (i) 29,474,569 shares (“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $4.75 per Share and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 4,210,527 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a price of $4.749 per”

RELMADA THERAPEUTICS, INC. issued 29,474,569 shares of common stock to certain institutional and accredited investors for $4.75 per Share.

“of approximately $160.0 million, an aggregate of (i) 29,474,569 shares (“Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price of $4.75 per Share and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 4,210,527 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a price of $4.749 per”

RELMADA THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $160.0 million (effective 2026-03-09).

“On March 9, 2026, Relmada Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).”

RELMADA THERAPEUTICS, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“July 22, 2025, Nasdaq notified the Company that it had approved the Company’s application to transfer its listing to the Nasdaq Capital Market. The Company’s securities will be transferred to the Nasdaq Capital Market at the opening of business on July 24, 2025. Nasdaq also approved a 180-day extension, or until January 19, 2026 (the “Compliance Period”), to regain compliance with the minimum bid price in accordance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s common stock must maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive”

RELMADA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business days ended January 17, 2025, the Company’s security did not maintain a minimum bid price of $1 per share. Nasdaq stated in its letter that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had a compliance period of 180 calendar days from the date of the notice (“Initial Compliance Period”), and that it may regain compliance if the closing bid of t”

RELMADA THERAPEUTICS, INC. engaged CBIZ CPAs P.C. as its auditor.

“On May 8, 2025, with the approval of the Company’s audit committee, CBIZ CPAs was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.”

RELMADA THERAPEUTICS, INC. dismissed Marcum LLP as its auditor.

“On May 8, 2025, the Company dismissed Marcum as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s audit committee approved the dismissal.”

RELMADA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecutive business days ended January 17, 2025, the Company’s security did not maintain a minimum bid price of $1 per share. Nasdaq stated in its letter that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days from the date of the notice (“Compliance Period”), and that it may regain compliance if the closing bid of the Compa”

RELMADA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“January 21, 2025, Relmada Therapeutics, Inc. (the “Company”) received a written notification from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the 30 consecu”

Paul Kelly was elected as Chief Operating Officer at RELMADA THERAPEUTICS, INC..

“Paul Kelly was elected by the Board of Directors (the “Board”) to the position of Chief Operating Officer of Relmada Therapeutics, Inc. (the “Company”).”

RELMADA THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: net income $98.8 million, EPS $3.28 per basic and diluted share.

“Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fourth quarter and full year ended December 31, 2023. (These results are preliminary and unaudited.)”

Cedric O'Gorman departed as Chief Medical Officer at RELMADA THERAPEUTICS, INC..

“On January 3, 2024, Dr. Cedric O’Gorman concluded his service as Chief Medical Officer of Relmada Therapeutics, Inc. (the “Company”), as mutually agreed upon between him and the Company.”

Cedric O’Gorman departed as Chief Medical Officer at RELMADA THERAPEUTICS, INC..

“On January 3, 2024, Dr. Cedric O’Gorman concluded his service as Chief Medical Officer of Relmada Therapeutics, Inc. (the “Company”), as mutually agreed upon between him and the Company.”

RELMADA THERAPEUTICS, INC. reported the nine months ended September 30, 2023 results: net income Net loss of $73.6 million, EPS $2.45 per share.

“Net loss for the nine months ended September 30, 2023 and 2022 was $73.6 million and $119.1 million, respectively. The Company had a net loss of $2.45 and $4.04 per share for the nine months ended September 30, 2023 and 2022, respectively.”

RELMADA THERAPEUTICS, INC. reported the three months ended September 30, 2023 results: net income Net loss of $22.0 million, EPS $0.73 per basic and diluted share.

“Net loss for the three months ended September 30, 2023, was $22.0 million, or $0.73 per basic and diluted share”

Eric Schmidt resigned as Member of the Board of Directors at RELMADA THERAPEUTICS, INC..

“On September 5, 2023, Eric Schmidt, a member of the Board of Directors (the “Board”) of Relmada Therapeutics, Inc. (the “Company”), notified the Company that he would resign from the Board, effective immediately.”

RELMADA THERAPEUTICS, INC. reported six months ended June 30, 2023 results: net income $51.6 million, EPS $1.72 per share.

“Net loss for the six months ended June 30, 2023 and 2022 was $51.6 million and $79.7 million, respectively. The Company had a net loss of $1.72 and $2.73 per share for the six months ended June 30, 2023 and 2022, respectively.”

RELMADA THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income $25.3 million, or $0.84 per basic and diluted share, EPS $0.84 per basic and diluted share.

“Net loss for the three months ended June 30, 2023, was $25.3 million, or $0.84 per basic and diluted share, compared with a net loss of $39.9 million, or $1.33 per basic and diluted share, for the three months ended June 30, 2022.”

RELMADA THERAPEUTICS, INC. shareholders approved Approval of an amendment to the 2021 Plan at the 2023-05-25 meeting.

“Proposal 3: Approval of an amendment to the 2021 Plan. Stockholders approved the amendment to the Company’s 2021 Plan described in”

RELMADA THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Independent Auditors at the 2023-05-25 meeting.

“Proposal 2: Ratification of Appointment of Independent Auditors. Stockholders approved the ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”

RELMADA THERAPEUTICS, INC. shareholders approved Election of Directors at the 2023-05-25 meeting.

“Proposal 1: Election of Directors. Stockholders elected the following nominees as directors to hold office until the 2026 Annual Meeting (i.e. as a Class II Director) and until his successor is elected and qualified.”

RELMADA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023, was $26.3 million, or $0.87 per basic and diluted share, EPS $0.87 per basic and diluted share.

“Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023.”

RELMADA THERAPEUTICS, INC. reported for the year ended December 31, 2022 results: net income -$157.0 million, EPS -$5.30.

“Net loss for the year ended December 31, 2022 and 2021 was $157.0 million and $125.8 million, respectively. The Company had a net loss of $5.30 and $7.16 per share for the year ended December 31, 2022 and 2021, respectively.”

Fabiana Fedeli was appointed as Director at RELMADA THERAPEUTICS, INC..

“increased the number of directors constituting the whole board from five to six and appointed Fabiana Fedeli as a Class I director of the Company”

RELMADA THERAPEUTICS, INC. amended License Agreement with Drs. Charles E. Inturrisi and Paolo Manfredi (effective 2022-12-27).

“On December 27, 2022, the Licensor and the Company entered into an Amendment No. 2 to the License Agreement extending the duration of the “Key Man” provisions of the License Agreement”

RELMADA THERAPEUTICS, INC. reported the nine months ended September 30, 2022 results: net income $119.1 million, EPS $4.04 per share.

“Net loss for the nine months ended September 30, 2022 and 2021 was $119.1 million and $91.4 million, respectively. The Company had a net loss of $4.04 and $5.36 per share for the nine months ended September 30, 2022 and 2021, respectively.”

RELMADA THERAPEUTICS, INC. reported the three months ended September 30, 2022 results: net income $39.4 million, EPS $1.31 per diluted share.

“The net loss for the three months ended September 30, 2022, was $39.4 million, or $1.31 per diluted share, compared with a net loss of $42.6 million, or $2.44 per diluted share, for the three months ended September 30, 2021.”